0000950170-24-073231.txt : 20240613
0000950170-24-073231.hdr.sgml : 20240613
20240613191120
ACCESSION NUMBER: 0000950170-24-073231
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240605
FILED AS OF DATE: 20240613
DATE AS OF CHANGE: 20240613
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Harwin Peter Evan
CENTRAL INDEX KEY: 0001663607
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38443
FILM NUMBER: 241042637
MAIL ADDRESS:
STREET 1: 200 BARR HARBOR DRIVE
STREET 2: SUITE 400
CITY: WEST CONSHOHOCKEN
STATE: PA
ZIP: 19428
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cogent Biosciences, Inc.
CENTRAL INDEX KEY: 0001622229
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 465308248
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 275 WYMAN STREET
STREET 2: 3RD FLOOR
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-945-5576
MAIL ADDRESS:
STREET 1: 275 WYMAN STREET
STREET 2: 3RD FLOOR
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Unum Therapeutics Inc.
DATE OF NAME CHANGE: 20180402
FORMER COMPANY:
FORMER CONFORMED NAME: Unum Therapeutics, Inc.
DATE OF NAME CHANGE: 20141014
4
1
ownership.xml
4
X0508
4
2024-06-05
0001622229
Cogent Biosciences, Inc.
COGT
0001663607
Harwin Peter Evan
C/O COGENT BIOSCIENCES, INC.
275 WYMAN STREET, 3RD FLOOR
WALTHAM
MA
02451
true
false
false
false
false
Stock Option (Right to Buy)
8.92
2024-06-05
4
A
false
44700
0.00
A
2034-06-05
Common Stock
44700
44700
D
This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2025 Annual Meeting of Stockholders.
Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
/s/ Evan D. Kearns, Attorney-in-Fact
2024-06-13